Anchor
FDA authorizes first standalone robotic blood-draw device
New CapabilitiesAletta, made by Netherlands-based Vitestro, wins US clearance to draw blood without a person guiding the needle
2 days ago: FDA authorizes AlettaNew here? Follow stories to track developments over time. Create a free account to get updates when stories you care about change.
Overview
Updated YesterdayA robot can now draw your blood. On August 19, 2026, the U.S. Food and Drug Administration (FDA) authorized Aletta, the first standalone device that finds a vein and takes a blood sample with no one guiding the needle by hand.
The machine uses near-infrared light and Doppler ultrasound to locate a vein and tell it apart from an artery. One trained phlebotomist can watch up to three devices at once. That ratio is the point: the United States is short on people trained to draw blood, and this is the first tool cleared to stretch the ones it has.
Why it matters
For the first time, a routine medical procedure most Americans go through can be done by a machine, with one human supervising three at a time.
Questions about this story
Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.
No questions yet — be the first to ask.
Key Indicators
3
Devices per supervisor
One trained phlebotomist can oversee up to three Aletta units at the same time.
4,000+
Patients in clinical testing
Vitestro says Aletta was validated across more than 4,000 patients before US clearance.
$70M
Funding raised March 2026
Vitestro's latest round, months before the FDA decision, to fund broader adoption.
18,400
Annual US phlebotomist openings
Bureau of Labor Statistics projection of average yearly openings through 2034.
Related Media
Vitestro Unveils Aletta™: The World's First Autonomous Robotic Phlebotomy Device™ (ARPD™)
Meet Aletta: The 1st FDA approved robotic blood draw device
2.6K views
1:17
Aletta, the world's first Autonomous Robotic Phlebotomy Device ...
Tamas Haidegger
13.4K views
1:55
Aletta is a robot that makes drawing blood completely automated.
Robots & AI Latest News
Images from Openverse under Creative Commons licenses. Videos from YouTube.
Voices
Curated perspectives — historical figures and your fellow readers.
Play
Exploring all sides of a story is often best achieved with Play.
Most of these play right now — no account needed. Sign up to save scores, keep a streak, and unlock Debate and Predict.
Log in
Sign Up
Higher or Lower
A number from this story, against one from elsewhere in the news — guess which is bigger, then keep the chain going. 5 rounds, 3 strikes; a miss costs a strike and resets your streak.
Example
Anchor
EU tariff revenue
$52B
Big for this kind of number
Mystery
Pentagon AI contract
?
Round 1
Streak: 0
Mystery
?
Keyboard: ↓/L lower · ↑/H higher
0 pts
Best streak: 0 · Rounds: 0
0 points — sign up to put that on the leaderboard.
Now try on this story
Connections
Sixteen names from the news. Find the four hidden groups of four. Four mistakes max.
Loading today's puzzle…
0/4 groups
Mistakes
Sign up to keep a daily streak — a new puzzle lands every day.
Now try on this story
Exit debate?
Your progress in this debate will be lost.
How it works
- 1 Two AI personas square off on this story.
- 2 You predict who'll win each round — correct picks earn XP.
- 3 One crossfire question is yours to fire. Pick it carefully.
Couldn't generate a topic
Select Your Champions
Choose one persona for each side of the debate
DEBATE TOPIC
Choose personas with different perspectives for a more dynamic debate.
SIDE A (PRO)
Select debater for this side:
No debate personas available right now.
SIDE B (CON)
Select debater for this side:
No debate personas available right now.
VS
Get ready to make your prediction...
Round of
Claim
Evidence
Stakes
Crossfire Answer
Closing Statement
Claim
Evidence
Stakes
Crossfire Answer
Closing Statement
Your Crossfire Question
Generating arguments...
Who's Got This Round?
Make your prediction before the referee scores
The referee scores both sides on
Correct predictions earn +20 XP
· Press 1 or 2 to pick
Evidence
40%
Logic
30%
Detail
20%
Style
10%
Round Results
Your Pick
Not this time
(%)
Overall Score
/10
Your Pick
Not this time
(%)
Overall Score
/10
Set the Crossfire
Pick the question both personas must answer in the final round
Crafting crossfire questions...
Choosing a question earns +10 XP crossfire bonus
🏆
Total XP Earned
Cred Change
Predictions
Debate Oracle! You called every round!
Sharp Instincts! You know your debaters!
The Coin Flip Strategist! Perfectly balanced!
The Contrarian! Bold predictions!
Inverse Genius! Try betting the opposite next time!
XP Breakdown
Base completion
+20 XP
Rounds played ( rounds x 5 XP)
+ XP
Correct predictions ( correct x 20 XP)
+ XP
Crossfire bonus
+10 XP
Accuracy
%
Prediction History
Round
You picked:
✓
✗
Now try on this story
Keep debating to level up your credibility and unlock achievements
People Involved
Organizations Involved
Vitestro
Medical robotics company
First firm to gain FDA clearance for an autonomous blood-draw device
A Utrecht-based medical robotics company that built Aletta, the first FDA-authorized standalone blood-draw robot.
U.S. Food and Drug Administration
Federal regulatory agency
Authorized Aletta through the De Novo pathway
The federal agency that reviews and clears medical devices for the US market.
Timeline
January 2017 August 2026
4 events
Latest: 2 days ago
Tap a bar to jump to that date
-
FDA authorizes Aletta
Latest RegulatoryThe FDA clears the first standalone robotic blood-draw device through the De Novo pathway, creating a new device category.
-
Vitestro raises $70 million
FundingA larger round funds broader clinical adoption, months before the US regulatory decision.
-
Vitestro raises $22 million
FundingThe company secures roughly €20 million to advance its autonomous blood-draw device and European rollout.
-
Vitestro founded in Utrecht
OriginToon Overbeeke and Brian Joseph start Vitestro to automate diagnostic blood collection.
Historical Context
3 moments from history that rhyme with this story — and how they unfolded.
July 2000
FDA clears the da Vinci Surgical System (2000)
The FDA cleared Intuitive Surgical's da Vinci system, letting surgeons operate through a robotic console instead of directly by hand. It was the first robotic system cleared for general soft-tissue surgery in the United States.
Then
Adoption was slow at first, limited by cost and surgeon training.
Now
Robotic surgery became routine for many procedures, and da Vinci systems are now in thousands of hospitals worldwide.
Why this matters now
It shows the usual arc for a first-of-its-kind clinical robot: clearance is the start, and real adoption takes years of training, pricing, and trust-building.
2015-2018
Theranos collapses over false blood-test claims (2015-2018)
Theranos claimed it could run hundreds of tests from a finger-prick of blood. Reporting and regulators found the technology did not work, and founder Elizabeth Holmes was later convicted of fraud.
Then
The company voided years of test results and shut down.
Now
It left lasting skepticism toward startups promising to reinvent blood testing.
Why this matters now
It is the cautionary contrast: Theranos avoided regulatory validation, while Aletta cleared the FDA on clinical data it can point to. The comparison is why FDA review matters here.
April 2018
FDA authorizes IDx-DR autonomous AI diagnostic (2018)
The FDA permitted marketing of IDx-DR, the first artificial-intelligence system cleared to make a medical diagnosis on its own. It screens for diabetic retinopathy from eye images without a doctor reading the result.
Then
It let primary-care clinics screen for the disease without an eye specialist on site.
Now
It set an early template for how the FDA reviews autonomous systems that act without a clinician in the loop.
Why this matters now
Like Aletta, it cleared the De Novo pathway and removed the human from a step long assumed to need one, raising the same questions about oversight and liability.